Please login to the form below

Not currently logged in
Email:
Password:

melanoma

This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

The first and so far only therapy of this type to reach the market is Amgen’s melanoma therapy Imlygic (talimogene laherparepvec or T-Vec, approved by the FDA in 2015,

Latest news

More from news
Approximately 76 fully matching, plus 277 partially matching documents found.

Latest Intelligence

  • Lighting the way Lighting the way

    The independent review's final report emerged in October 2016, with potential implications for treatment access for a number of conditions, with myeloma, melanoma and dementia highlighted in the publication.

  • Managed Access Programmes: a powerful source of real-world insight Managed Access Programmes: a powerful source of real-world insight

    Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded

  • Managed Access Programmes: a powerful source of real-world insight Managed Access Programmes: a powerful source of real-world insight

    Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded

  • Deal Watch February 2016 Deal Watch February 2016

    The lead siDNA, DT01, has been tested in a phase I/II study in metastatic melanoma and Onxeo plans to investigate the potential of this approach in various solid tumours.

  • Pharma deals during July 2014 Pharma deals during July 2014

    In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is ... FDA approved for late-stage melanoma.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Packer Forbes appoints Jade McCudden Packer Forbes appoints Jade McCudden

    McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.

  • Array appoints Victor Sandor chief medical officer Array appoints Victor Sandor chief medical officer

    This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Jonathan Dickinson joins Ariad from BMS Jonathan Dickinson joins Ariad from BMS

    The drug made $786m worldwide during 2012 following approvals to treat adult patients with metastatic melanoma who have received prior therapy.

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics